The first unequivocal success for Gene Therapy was reported in April 2000 for X-SCID patients. Pioneering stem cell/gene therapy clinical trials are the focus of this book. Therapy successes such as the X-SCID trial and improved ADA-SCID ones are presented together with pioneering angio/vasculogenic clinical trials mediated either by transient gene
Stem cells provide for life-long cell replacement in tissues and organs, and have inherent homing abilities that are critical in therapeutic applications. Stem cells are also the driving force of cancer where genetic/epigenetic alterations culminate in tumorigenesis either in tissue stem cells or in some of their derivatives. As a rare subset of the tumor, cancer stem cells are the only drive of tumor initiation/propagation. Autologous and cancer stem cells are thus the key targets of 1) long-term and transient-regenerative/epigenetic gene therapy and 2) of recurrence-free anticancer therapy, respectively. While cancer stem cell gene therapy still needs time to accomplish, autologous stem cells have been instrumental in the first unequivocal successes for gene therapy whereby ex vivo retrovirally corrected hematopoietic stem cells have been returned to the patients. This timely book presents 1) the aforementioned stem cell gene therapy achievements that rely on random-integration of therapeutic transgenes into host chromosomes and 2) emerging experimental approaches aimed at eliminating random-integration oncogenic hazards through site-specific integration or gene targeting. Breakthrough endonuclease-boosted gene targeting for gene correction (inherited diseases) or targeted integration of therapeutic transgenes (other disorders) culminating in an efficiency compatible with clinical trials is one of the highlights of the book. Highlights also include the pioneering transplantation of adult pluripotent stem cells as a substitute for tissue-specific stem cells, thereby pinpointing the invaluable potential for stem cell gene therapy applications of autologous cells able to contribute to all three germ layers. Stem cell gene therapy is thus discussed in terms of 1) magnifying stem cell therapeutic homing through transient regenerative gene therapy and 2) of tackling most pathologies (including mitochondrial DNA diseases and ageing disorders) through stem cell repopulation dynamics into appropriate niches (long-term engraftment) and tissues (cell turn-over). Regarding cancer stem cell gene therapy, focus is on both the increasing number of identified tissue-specific cancer stem cells as the ultimate therapeutic targets and on the development of armed stem cells as tumor-homing vectors for targeted anticancer therapy. Sample Chapter(s). Introduction: Toward a Universal Platform for Autologous Stem Cell Gene Therapy (335 KB). Chapter 1: Stem Cell Gene Therapy for ADA-Deficiency without Myelopreparative Conditioning (318 KB). Contents: Introduction: Toward a Universal Platform for Autologous Stem Cell Gene Therapy; Long-term Stem Cell Gene Therapy: From Current Clinical Random-Integration Achievements to Stem Cell Gene Targeting/Cybridization: From Pioneering Clinical Retroviral Gene Therapy to Experimental Site-Specific Integrative Gene Therapy; Stem Cell Gene Targeting/Cybridization: Toward Endonuclease-Boosted Gene Repair/Alteration, Custom Site-Specific Integrative Gene Therapy and Transmitochondrial Therapy/Rejuvenation; Adult Pluripotent Stem Cells: Emerging Stem Cell/Gene Therapy Breakthrough; Cancer Stem Cell Gene Therapy: Cancer Stem Cells as Breakthrough Targets of Cancer Gene Therapy; Armed Stem Cells as Tumor-Homing Vectors for Cancer Gene Therapy. Readership: Clinicians, scientists, physicians, veterinarians, dentists, pharmacists/chemists, interested in an ongoing medical/veterinarian breakthrough that is expected to revolutionize the practice of Medicine/Dentistry and that relies on cell biology, molecular biology/genetics, developmental biology, biochemistry, molecular pathology and animal science.
Playing Tough is an entertaining and thoroughly enlightening look at the unique and surprisingly outsized role that sports have played in politics and history. Ever since the bread and circuses of Rome, sports have been used as a tool to entertain the masses and to instill civic pride. Abrams shows both the positive and the negative ways in which sports and politics have coalesced, from the rabid nationalism of the 1936 Nazi Olympics, the political grudge match of the Louis and Schmeling fights, and the "futbol war" between Honduras and Costa Rica to the inspiring stories of South Africa's rugby nation-building and Muhammad Ali's brave antiwar stance, which nearly cost him his career. Abrams is an informed and impassioned writer who chronicles the profoundly creative and destructive influence that sports have on the political life of our nation and the world. This book will be of interest to any and all sports and politics enthusiasts and is a wonderful introduction for course creation and adoption.
Essential for ob/gyn physicians, primary care physicians, and any health care provider working with pregnant or postpartum women, Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 12th Edition, puts must-know information at your fingertips in seconds. An easy A-to-Z format lists more than 1,400 of the most commonly prescribed drugs taken during pregnancy and lactation, with detailed monographs designed to provide the most essential information on possible effects on the mother, embryo, fetus, and nursing infant.
Pulmonary rehabilitation programmes are now a fundamental part of the clinical management of patients with chronic respiratory diseases. This comprehensive reference book places pulmonary rehabilitation within the wider framework of respiratory disease, and the health burden that this now poses worldwide. Part one of the book examines the evidence supporting the use of pulmonary rehabilitation programmes, new trends and socio-economic implications, and the scientific bases of techniques used. In part two, the reader is given important guidance on assessing patients for rehabilitation and what the cost implications are for patients and the health care system. The last part of the book provides a general overview and discusses specific problems of delivering pulmonary rehabilitation. Throughout the book, contributions drawn from a broad range of countries compare and contrast practice around the world where differences have developed, and discuss the clinical evidence that supports current thinking.
Shareholder engagement with publicly listed companies is often seen as a key means to monitor corporate malpractices. In this book, the authors examine the corporate governance roles of key institutional investors in UK corporate equity, including pension funds, insurance companies, collective investment funds, hedge and private equity funds and sovereign wealth funds. They argue that institutions’ corporate governance roles are an instrument ultimately shaped by private interests and market forces, as well as law and regulatory obligations, and that policy-makers should not readily make assumptions regarding their effectiveness, or their alignment with public interest or social good.
An A-Z listing of drugs by generic name. Each monograph summarizes the known and/or possible effects of the drug on the fetus. It also summarizes the known/possible passage of the drug into the human breast milk. A careful and exhaustive summarization of the world literature as it relates to drugs in pregnancy and lactation. Each monograph contains six parts: Generic US name Pharmacologic class Risk factor Fetal risk summary Breast feeding summary References Features for this edition include: 1200 commonly prescribed drugs including 105 new drugs New mobile application to access the content on the go* Cross-referenced combination drugs New list of drugs contraindicated during breastfeeding New list of drugs contraindicated in pregnancy List of drugs known to cause human developmental toxicity More summaries at the beginning for pregnancy and breastfeeding Brand new trim size 8.5 x 11 4-color design Consistently formatted throughout Companion site includes fully searchable text and updates from the Briggs newsletter *App included with the book is a free version with limited content. An in-app purchase is available for an upgrade to the full app content. With the ever changing drug information and guidelines, make sure you have the most current edition of Briggs Drugs in Pregnancy and Lactation to provide your patients with the best care.
The first unequivocal success for Gene Therapy was reported in April 2000 for X-SCID patients. Pioneering stem cell/gene therapy clinical trials are the focus of this book. Therapy successes such as the X-SCID trial and improved ADA-SCID ones are presented together with pioneering angio/vasculogenic clinical trials mediated either by transient gene
Stem cells provide for life-long cell replacement in tissues and organs, and have inherent homing abilities that are critical in therapeutic applications. Stem cells are also the driving force of cancer where genetic/epigenetic alterations culminate in tumorigenesis either in tissue stem cells or in some of their derivatives. As a rare subset of the tumor, cancer stem cells are the only drive of tumor initiation/propagation. Autologous and cancer stem cells are thus the key targets of 1) long-term and transient-regenerative/epigenetic gene therapy and 2) of recurrence-free anticancer therapy, respectively. While cancer stem cell gene therapy still needs time to accomplish, autologous stem cells have been instrumental in the first unequivocal successes for gene therapy whereby ex vivo retrovirally corrected hematopoietic stem cells have been returned to the patients. This timely book presents 1) the aforementioned stem cell gene therapy achievements that rely on random-integration of therapeutic transgenes into host chromosomes and 2) emerging experimental approaches aimed at eliminating random-integration oncogenic hazards through site-specific integration or gene targeting. Breakthrough endonuclease-boosted gene targeting for gene correction (inherited diseases) or targeted integration of therapeutic transgenes (other disorders) culminating in an efficiency compatible with clinical trials is one of the highlights of the book. Highlights also include the pioneering transplantation of adult pluripotent stem cells as a substitute for tissue-specific stem cells, thereby pinpointing the invaluable potential for stem cell gene therapy applications of autologous cells able to contribute to all three germ layers. Stem cell gene therapy is thus discussed in terms of 1) magnifying stem cell therapeutic homing through transient regenerative gene therapy and 2) of tackling most pathologies (including mitochondrial DNA diseases and ageing disorders) through stem cell repopulation dynamics into appropriate niches (long-term engraftment) and tissues (cell turn-over). Regarding cancer stem cell gene therapy, focus is on both the increasing number of identified tissue-specific cancer stem cells as the ultimate therapeutic targets and on the development of armed stem cells as tumor-homing vectors for targeted anticancer therapy. Sample Chapter(s). Introduction: Toward a Universal Platform for Autologous Stem Cell Gene Therapy (335 KB). Chapter 1: Stem Cell Gene Therapy for ADA-Deficiency without Myelopreparative Conditioning (318 KB). Contents: Introduction: Toward a Universal Platform for Autologous Stem Cell Gene Therapy; Long-term Stem Cell Gene Therapy: From Current Clinical Random-Integration Achievements to Stem Cell Gene Targeting/Cybridization: From Pioneering Clinical Retroviral Gene Therapy to Experimental Site-Specific Integrative Gene Therapy; Stem Cell Gene Targeting/Cybridization: Toward Endonuclease-Boosted Gene Repair/Alteration, Custom Site-Specific Integrative Gene Therapy and Transmitochondrial Therapy/Rejuvenation; Adult Pluripotent Stem Cells: Emerging Stem Cell/Gene Therapy Breakthrough; Cancer Stem Cell Gene Therapy: Cancer Stem Cells as Breakthrough Targets of Cancer Gene Therapy; Armed Stem Cells as Tumor-Homing Vectors for Cancer Gene Therapy. Readership: Clinicians, scientists, physicians, veterinarians, dentists, pharmacists/chemists, interested in an ongoing medical/veterinarian breakthrough that is expected to revolutionize the practice of Medicine/Dentistry and that relies on cell biology, molecular biology/genetics, developmental biology, biochemistry, molecular pathology and animal science.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.